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Abstract 
Endometrial stromal sarcoma (ESS) is typi-
cally  associated  with  metastasis  to  the
abdomen,  pelvis,  and  lung.  We  found  three
case  reports  of  ESS  metastasis  to  the  bone
(two to the thoracic spine, and one to the pari-
etal bone). Our objective is to review the liter-
ature on ESS spinal and intracranial metas-
tases and, report the first case of ESS metasta-
tic to the lumbar paraspinal region and sphe-
noid bone. A 53-year-old female with ESS sta-
tus-post  radiation,  chemotherapy,  and  pelvic
exenteration surgery presented with right hip
weakness, back pain, and radicular leg pain
that were explained by chemotherapy-induced
neuropathy,  radiation-induced  lumbosacral
plexopathy, and femoral nerve and obturator
nerve  injury  during  pelvic  exenteration  sur-
gery. During routine positron emission tomog-
raphy, we found metastasis to the L3 lumbar
spinal  region.  L3  laminectomy  and  subtotal
resection  of  the  mass  was  performed  with
tumor residual in the neuroforamina and pedi-
cles.  One  month  later,  magnetic  resonance
imaging  (MRI)  performed  for  persistent
headaches revealed a large lesion in the sphe-
noid bone that was biopsied transsphenoidally
with the same diagnosis, but no further sur-
gery  was  performed.  She  is  intolerant  of
chemotherapy and currently undergoing whole
brain  radiation.  Delay  in  the  diagnosis  and
management of lumbar paraspinal and sphe-
noid bone metastasis of ESS likely occurred
because of the uniqueness of the location and
aggressiveness of ESS metastasis. Health care
providers  should  be  aware  of  potentially
aggressive metastasis of ESS to bone, in par-
ticular  the  unusual  locations  of  the  lumbar
paraspinal region and sphenoid bone.
Introduction
Endometrial  stromal  sarcoma  (ESS)  is  a
rare form of uterine cancer, with fewer than
450  new  cases  diagnosed  annually  in  the
United States.1,2 Most ESSs are clinically indo-
lent, histologically classified as low-grade, with
a  5-year  survival  rate  of  65%.3 In  contrast,
high-grade or undifferentiated ESS cases are
more aggressive with less than a 25% 5-year
survival.4 Both low- and high- grade ESS are
treated  surgically  with  a  hysterectomy,  with
some  evidence  from  retrospective  studies
showing that adjuvant radiotherapy can reduce
the recurrence of disease.4,5 Recurrence of or
advanced disease can also be treated with sur-
gical resection and adjuvant hormone therapy
in low-grade ESS and palliative chemotherapy
in high-grade ESS.1
When  metastasis  occurs,  ESS  typically
spreads  to  the  abdomen,  pelvis,  and  lung.5-8
Rarely  does  ESS  metastasizes  to  bone.  We
found two reported cases of ESS with spinal
metastasis – both in the thoracic spine.9,10 One
case appeared 18 years and the other 7 years,
after initial ESS treatment.9,10 We found one
report of cranial ESS metastasis to the parietal
bone, which occurred 1 year after initial ESS
diagnosis.11 We  report  here  the  first  known
case  of  metastasis  to  the  lumbar  paraspinal
region and sphenoid bone, which occurred less
than 2 years after initial ESS diagnosis, again
demonstrating  the  ability  of  this  tumor  to
metastasize to bone.
Materials and Methods
This case report was developed from direct
patient  clinical  encounters,  events  that  took
place in the operating room, review of medical
records,  review  of  radiographic  studies,  and
pathology  slides.  An  interdisciplinary  group
from neurosurgery, gynecologic oncology, and
pathology reviewed, discussed, and developed
this case report.
Results
A  53-year-old  Caucasian  female  with  ESS
was referred to our neurosurgery outpatient
clinic in March 2010 after a routine position
resonance imaging (PET) scan 2 months ear-
lier revealed increased uptake in the L3 spin-
ous process (Figure 1). Magnetic resonance
imaging (MRI) of the lumbar spine in March
2010 revealed a 3-centimeter heterogeneously
enhancing mass involving the lamina, spinous
process,  right  pedicle,  and  right  transverse
process  of  L3,  with  expansion  into  the
paraspinous muscles and without involvement
of the dorsal fascia or epidural space (Figure
2).
The patient initially presented to her pri-
mary care physician 3 years earlier with symp-
toms of urinary incontinence, and a workup
revealed  uterine  fibroids.  She  underwent
supracervical  hysterectomy.  The  pathology
report identified multiple leiomyomas within
the myometrium, some with myxoid change.
One year later, the patient developed worsen-
ing urinary incontinence. She was found to
have a large pelvic mass. Core biopsy showed
a  myxoid  spindle  cell  lesion  with  reactivity
against  desmin  and  weak  reactivity  against
muscle-specific actin. Immunohisto  chemistry
against CD10 was non reactive. The features
were interpreted as suggestive of leiomyosar-
coma. Biopsies of additional intra-abdominal
lesions  were  morphologically  similar,  but
these tumors failed to react against muscle-
specific actin, smooth muscle actin and CD10.
Therefore,  a  diagnosis  of  primary  ESS  was
favored.
The patient underwent preoperative radia-
tion therapy followed by extensive resection of
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[page 86] [Rare Tumors 2011; 3:e27]the  intraabdominal  tumor.  Discovery  of
metastatic disease led to an end colostomy and
palliative  chemotherapy  with  taxotere  and
ifos/Adria. Because of intolerable side effects
(including  leukocytosis,  alopecia,  skin
changes, fatigue, and nausea) and local pro-
gression of disease, she was switched to hor-
monal therapy with megace, then an aromatase
inhibitor. Her disease was stable for year on
hormonal therapy, and then the patient under-
went  pelvic  exenteration  (hemicolectomy  in
October  2008;  cystectomy,  proctectomy,  and
partial vaginectomy in July 2009). Evaluation of
the resected colon, urinary bladder and vagina
again showed a spindle cell tumor morphologi-
cally similar to that seen in the patient’s previ-
ous biopsies and resection, but also small areas
of high-grade sarcoma. This specimen showed
reactivity with anti-CD10 antibody and no reac-
tivity against desmin, actin, myoD, or S100 pro-
tein. The findings were interpreted as consis-
tent with ESS, predominately low-grade, with
focal areas with high-grade features.
The patient’s paraspinal mass was unusual-
ly aggressive. Two months after pelvic exenter-
ation surgery, the patient reported hip flexion
and abduction weakness. Diagnostic consider-
ations  included  chemotherapy-induced  neu-
ropathy,  radiation-induced  lumbosacral  plex-
opathy,  and  iatrogenic  femoral  nerve  injury.
Her obturator nerve was resected during the
surgery. Electromyogram showed right obtura-
tor neuropathy, which was believed to explain
her right hip flexion and abduction weakness.
At  the  time  of  the  routine  PET  scan  that
revealed the lumbar mass (January 2010), she
had no back pain. One month later, she devel-
oped dull aching lower back pain, with occa-
sional stabbing on the right, and paresthesias
bilaterally  to  the  feet.  Physical  examination
revealed no neurologic deficits and no palpable
mass in the lumbar region. An MRI of the cer-
vical and thoracic spine showed a small, round-
ed, hypointensity of the C4 vertebral body but
was  otherwise  normal.  A  bone  scan  showed
suspected metastases in the bilateral femoral
diaphyses,  left  humeral  head,  right  seventh
rib, and mid-lumbar spine. The original PET
scan  from  January  2010  also  showed  mild
enlargement of a right middle lobe lung mass
and other bony metastases.
Despite the presence of other bony and soft-
tissue metastases, we decided to decompress
the lumbar mass because of the patient’s good
performance status, intolerance to chemother-
apy, the large size of the lesion that correlated
with the imaging and limited her daily activi-
ties, and the expectation of a minimally morbid
surgery given the predominantly dorsal loca-
tion of the lesion. The goals of surgery were to
improve her hip and back pain and debulk the
tumor to facilitate adjuvant treatment.
Intraoperatively,  the  tumor  protruded
through the lumbar fascia. A clear plane was
evident between the tumor and paraspinous
muscles in some areas, but roughly 60% of the
tumor was blended with the surrounding mus-
cle and the L3 spinous process was partially
eroded. After L3 laminectomy, we found signif-
icant  epidural  tumor  extension  with  adher-
ence to the dura. Epidural tumor in the central
canal was resected, but tumor remained in the
lateral recess traveling out the neural foramen
on the right at L2–3 and in the right L3 pedicle
Figure 1. PET/computed tomography showing increased uptake and erosion of the spin-
ous process in the dorsal L3 region.
Figure 2. Preoperative lumbar MRI images.
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the patient’s known multiple metastases, we
had not planned for gross total resection. We
did  not  perform  fusion  and  stabilization
because  the  procedure  is  associated  with  a
higher complication rate, and longer recovery
time, and felt that it would not affect overall
survival. Further, because of her planned radi-
ation therapy, she had a higher risk of non
union. Total volume of resected tumor submit-
ted to pathology was 181.2 cm3 compared with
preoperative volume estimated by MRI to be 27
cm3.  This  change  represented  a  5.7-fold
increase in total tumor volume over a 6-week
period.  The  pathology  report  identified  a
malignant myxoid spindle cell lesion with pre-
dominately low-grade features and focal high-
grade morphology which was consistent with
origin from the patient’s previously diagnosed
sarcoma (Figure 3). The patient then received
palliative radiation to the lumbar paraspinal
region. She was offered systemic chemothera-
py, but refused because of her previous experi-
ence  with  the  chemotherapy-related  side
effects.
During workup for a persistent headache 1
month later, MRI of the head revealed an avid-
ly enhancing expansile mass in the body of the
sphenoid bone, with soft tissue extension into
the sphenoid sinus and posterior ethmoid air
cells. Abnormal marrow replacement surround-
ed the area in the lesser wing of the sphenoid
bone  and  clivus  (Figure  4).  A  stereotactic-
assisted  transsphenoidal  biopsy  was  per-
formed without complication. The lesion was
diagnosed  as  a  myxoid  sarcoma  with
histopathological  features  similar  to  those
seen  in  the  preceding  biopsy  and  resection
specimens (Figure 5). The tumor represented
had  features  of  a  low  histologic  grade.  The
patient is currently receiving whole brain radi-
ation. No chemotherapy was administered due
to her history of intolerance.
Discussion
This  case  represents  a  significant  and
unusual  presentation  for  several  reasons:  i)
ESS rarely metastasizes to bone; this is the
first reported case of ESS metastasis to the
lumbar spine and sphenoid bone; ii) contrary
to most reported cases of ESS, this tumor grew
very  aggressively;  iii)  there  was  a  delay  in
diagnosis due to the broad differential of hip
weakness, back pain, radicular leg pain, and
headache in patients receiving treatment for
ESS;  iv)  these  rare  tumors  pose  significant
challenges to pathologic diagnosis; v) limited
clinical information about spinal ESS metasta-
sis complicates treatment decision-making.
Metastasis  of  ESS  typically  occurs  in  the
pelvic, abdominal, and lung regions. This case
study demonstrates the ability to ESS to metas-
tasize  aggressively  to  bone.  Adding  to  the
paucity of case studies of ESS bone metastasis
(two to the thoracic region, one to the parietal
Figure  3.  Postoperative  lumbar  MRI
images. (A) Sagittal T1 with gadolinium.
(B) Axial T1 with gadolinium.
Figure  4.  MRI  images  of  the  head  demonstrating  large  sellar/sphenoid  sinus  mass.
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can also spread to the lumbar spine and sphe-
noid bone. On bone scan, this patient also had
lesions in the bilateral femoral diaphyses, left
humeral  head,  and  right  seventh  rib.  MRI
showed a lesion in the C4 vertebra. Although
no  biopsy  was  performed  in  these  other
regions, we have high clinical suspicion that
these  areas  may  also  have  ESS  metastasis.
This patient was unique because her mass was
in the lumbar region without vertebral body
involvement. The tumor extended into the sur-
rounding  soft  tissues  and  epidural  space,
which has not been previously reported.
It is unclear how long the lesion had been
growing and whether the dramatic expansion
of the mass in the 6 weeks prior to surgery rep-
resented a transformation of a previously indo-
lent lesion. Throughout 2009 while being treat-
ed for various abdominopelvic issues, includ-
ing a suspected presacral abscess, the patient
had multiple computed tomography (CT) scans
of he abdomen and pelvis. At the time, no lum-
bar spine lesion was identified, though abdom-
inal  CT  is  not  ideal  for  examining  lumbar
spine  pathology.  However,  in  retrospect  we
found erosion of the L3 spinous process and a
1.5-centimeter  soft  tissue  mass  that  was
missed  in  the  original  August  2009  report
(Figure  6).  In  a  minimally  symptomatic  to
asymptomatic patient, it is doubtful that rou-
tine  detailed  imaging  of  the  spine,  such  as
screening MRI, would have been cost-effective.
An appropriate workup, including electromyog-
raphy testing, did not suggest a lumbar source
for the patient’s hip pain, so the suspicion of
lumbar disease was not raised until the rou-
tine PET scan found her tumor. Although there
was a delay in treatment, it is unclear if this
affected  her  outcome  given  the  aggressive
nature of the ESS tumor.
This case also highlights the challenges of
correctly  diagnosing  ESS,  which  is  rare  and
difficult  to  characterize  histopathologically.12
These diagnostic challenges were evident in
this patient’s pathology reports, which showed
an evolution in the diagnosis from leiomyoma
with myxoid degeneration through a neoplasm
with  features  favoring  leiomyosarcoma,  ulti-
mately to ESS. The difficulty of accurately diag-
nosing  ESS  impacts  the  treatment  decision-
making. There is evidence that TAH-BSO and
adjuvant radiotherapy can be effective for both
low and high grade ESS. However, additional
adjuvant  treatments  recommendations  differ
depending on the grade of ESS (hormonal and
surgical  treatment  for  low-grade,  and
chemotherapy  for  high-grade).1 In  our
patient’s case, the decision to operate despite
the presence of other metastases was based on
the low-grade of the ESS tumor, her good per-
formance status, size of the lesion, and expec-
tation of a minimally morbid surgery. We did
not realize how aggressive this tumor was pre-
operatively.
In conclusion, delays in diagnosis and man-
agement  in  this  case  report  likely  occurred
because of the uniqueness of the locations and
aggressiveness  of  ESS  metastasis.  It  is  our
hope that this report will increase awareness
among health care providers of the potentially
aggressive metastasis of ESS to the bone, in
particular to the craniospinal axis.
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